Please assess the completion status of the following clinical trial:

Trial Title: Mild, Moderate and Severe Renal Impairment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.~* Subject with renal impairment, as determined at Screening, with creatinine clearance as calculated by the Cockcroft-Gault formula of 60 to \< 90 mL/min (mild impairment), 30 to \< 60 mL/min (moderate impairment), or 15 to \< 30 mL/min (severe impairment), or a matched control subject (by age and body mass index) with a creatinine clearance of ≥ 90 mL/min.~* Subject has a Screening serum urate level ≥ 4.5 mg/dL and ≤ 10 mg/dL~Exclusion Criteria:~* Subject has a history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.~* Subject has a history or suspicion of kidney stones.~* Subject has a history of asthma.~* Subject has undergone major surgery within 3 months prior to Day 1.~* Subject has donated blood or experienced significant blood loss (\> 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Mild renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 2: Moderate renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 3: Severe renal impairment (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted
- Cohort 4: Control subjects with normal renal function (Type: EXPERIMENTAL): RDEA3170 15 mg once daily fasted

Based on this trial design, predict the completion outcome and termination type (if applicable).